Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stimulate insulin secretion, decrease glucagon release from the pancreas, improve insulin sensitivity, and increase feelings of satiety by targeting receptors in the brain, resulting in sustained weight reduction in individuals both with and without T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.